MET mutations in cancers of unknown primary origin (CUPs)

Human Mutation

Volumn 32, Issue 1, 2011, Pages 44-50

  Stella, Giulia M ^a,b   Benvenuti, Silvia ^a   Gramaglia, Daniela ^a   Scarpa, Aldo ^c   Tomezzoli, Anna ^c   Cassoni, Paola ^a   Senetta, Rebecca ^a   Venesio, Tiziana ^a   Pozzi, Ernesto ^b   Bardelli, Alberto ^a   Comoglio, Paolo M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Invasive growth; MET; Metastases; Somatic mutation; Tyrosine kinase

Indexed keywords

GENOMIC DNA; SCATTER FACTOR RECEPTOR; SEMAPHORIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER OF UNKNOWN PRIMARY SITE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION;

AGED; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASMS, UNKNOWN PRIMARY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET;

EID: 78650426144     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21374     Document Type: Article

References (42)

1. Boccaccio C, Comoglio PM. 2006. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6:637-645.
2. Briasoulis E, Pavlidis N, Felip E. 2009. Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow up. Ann Oncol 20:iv154-iv155.
3. Buhard O, Cattaneo F, Wong YF, Yim SF, Friedman E, Flejou JF, Duval A, Hamelin R. 2006. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol 24:241-251.
4. Casorzo L, Luzzi C, Nardacchione A, Picciotto F, Pisacane A, Risio M. 2005. Fluorescence in situ hybridization (FISH) evaluation of chromosomes 6, 7, 9 and 10 throughout human melanocytic tumorigenesis. Melanoma Res 15:155-160.
5. Cipriani NA, Abidoye OO, Vokes E, Salgia R. 2009. MET as a target for treatment of chest tumors. Lung Cancer 63:169-179.
6. Comoglio PM, Boccaccio C. 2001. Scatter factors and invasive growth. Semin Cancer Biol 11:153-165.
7. Comoglio PM, Giordano S, Trusolino L. 2008. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516.
8. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM. 2000. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19:1547-1555.
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043.
10. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-797.
11. Gherardi E, Youles ME, Miguel RN, Blundell TL, Iamele L, Gough J, Bandyopadhyay A, Hartmann G, Butler PJ. 2003. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 100:12039-12044.
12. Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, Birchmeier C, Swiatek P, Bronson R, Vande Woude G. 2004. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci USA 101:17198-17203.
13. Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D. 2008. Gene expression profiling to identify the histogenic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 26:4435-4441.
14. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA. 2008. Systemic spread is an early step in breast cancer. Cancer Cell 13:56-58.
15. Kong-Beltran M, Stamos J, Wickramasinghe D. 2004. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 6:75-84.
16. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF. 2000. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19:4947-4953.
17. Lorenzato A, Olivero M, Patanè S, Rosso E, Oliaro A, Comoglio PM, Di Renzo MF. 2002. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res 62:7025-7030.
18. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. 2008. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47:1025-1037.
19. Michieli P, Basilico C, Pennacchietti S, Maffè A, Tamagnone L, Giordano S, Bardelli A, Comoglio PM. 1999. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18:5221-5231.
20. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. 2004. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6:61-73.
21. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. 2005. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279-286.
22. Park SY, Kim BH, Kim JH, Lee S, Kang GH. 2007. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 131:1561-1567.
23. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY. 1999. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59:307-310.
24. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. 2003. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347-361.
25. Pentheroudakis G, Golfinopoulos V, Pavlidis N. 2007. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 43:2026-2036.
26. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM. 1994. A multifunctional docking site mediates signalling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77:261-271.
27. Prat M, Crepaldi T, Gandino L, Giordano S, Longati P, Comoglio P. 1991. C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol 11:5954-5962.
28. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R. 2007. c-MET is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13:2246-2253.
29. Regelink G, Brouwer J, de Bree R, Pruim J, van der Laan BF, Vaalburg W, Hoekstra OS, Comans EF, Vissink A, Leemans CR, Roodenburg JL. 2002. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging 29:1024-1030.
30. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. 1993. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8:1195-1202.
31. Rossi G, Nannini N, Costantini M. 2009. Morphology and more specific immunohistochemical stains are fundamental prerequisites in detection of unknown primary cancer. J Clin Oncol 27:649-650.
32. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73.
33. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. 2009. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021-3031.
34. Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR. 2007. The role of 2-deoxy-2-[F-18]fluoro-D glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 109:292-299.
35. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R. 2002. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123:1804-1811.
36. Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM. 1999. Plexins are a large family of receptors for transmembrane, secreted and GPI-anchored semaphorins in vertebrate. Cell 99:71-80.
37. Taylor JR. 1982. An introduction to error analysis. Mill Valley, CA; University Science Books.
38. Terranova VP, Hujanen ES, Loeb DM, Martin GR, Thornburg L, Glushko V. 1986. Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci USA 83:465-469.
39. Trusolino L, Comoglio PM. 2002. Scatter-factors and semaphoring receptors: cell signaling for invasive growth. Nat Rev Cancer 4:289-300.
40. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. 2008. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26:4442-4448.
41. Vigna E, Naldini L. 2000. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidate for gene therapy. J Gene Med 2:308-316.
42. Weinberg RA. 2008. Leaving home early: reexamination of the canonical models of tumor progression. Cancer Cell 14:283-284.